LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.

A. Michelotti,Marco de Scordilli,Elisa Sperti,Roberta Mazzeo,C Corvaja,Giacomo Aimar,Lorenzo Gerratana,Michela Guardascione,Federica Rampin,S. Buriolla,Paola Di Nardo,Valentina Fanotto,V J Andreotti,Michele Bartoletti,E Bertoli,Claudia Noto,Angela Buonadonna,Massimo Di Maio,Elena Ongaro,Fabio Puglisi

LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.

2021

e16102Background: Lactate dehydrogenase (LDH) is recognized as indirect marker of tumor hypoxia and angiogenesis for several solid tumors. Ramucirumab is the first antiangiogenic agent approved for...

Keywords:

Cancer research
advanced gastric cancer
Medicine
Lactate dehydrogenase
Ramucirumab
Angiogenesis
Line (text file)
second line treatment
prognostic factor
Tumor hypoxia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations